S&P 500   3,852.36
DOW   32,920.46
QQQ   303.59
Mullen Automotive Stock, The Tide Has Turned
Profit From the Commercial Solar Boom? (Ad)
Energizer Holdings Inc; Losing Power Or Electrifying Time To Buy?
What do Mastercard Earnings Indicate About Consumer Spending?
Profit From the Commercial Solar Boom? (Ad)
How to Find Penny Stocks to Invest and Trade
ONSemi Is Marching Higher On Great Results
Profit From the Commercial Solar Boom? (Ad)
What Tyson Foods Q1 Means For Staples Stocks
Can Cummins Power To A New High? 
S&P 500   3,852.36
DOW   32,920.46
QQQ   303.59
Mullen Automotive Stock, The Tide Has Turned
Profit From the Commercial Solar Boom? (Ad)
Energizer Holdings Inc; Losing Power Or Electrifying Time To Buy?
What do Mastercard Earnings Indicate About Consumer Spending?
Profit From the Commercial Solar Boom? (Ad)
How to Find Penny Stocks to Invest and Trade
ONSemi Is Marching Higher On Great Results
Profit From the Commercial Solar Boom? (Ad)
What Tyson Foods Q1 Means For Staples Stocks
Can Cummins Power To A New High? 
S&P 500   3,852.36
DOW   32,920.46
QQQ   303.59
Mullen Automotive Stock, The Tide Has Turned
Profit From the Commercial Solar Boom? (Ad)
Energizer Holdings Inc; Losing Power Or Electrifying Time To Buy?
What do Mastercard Earnings Indicate About Consumer Spending?
Profit From the Commercial Solar Boom? (Ad)
How to Find Penny Stocks to Invest and Trade
ONSemi Is Marching Higher On Great Results
Profit From the Commercial Solar Boom? (Ad)
What Tyson Foods Q1 Means For Staples Stocks
Can Cummins Power To A New High? 
S&P 500   3,852.36
DOW   32,920.46
QQQ   303.59
Mullen Automotive Stock, The Tide Has Turned
Profit From the Commercial Solar Boom? (Ad)
Energizer Holdings Inc; Losing Power Or Electrifying Time To Buy?
What do Mastercard Earnings Indicate About Consumer Spending?
Profit From the Commercial Solar Boom? (Ad)
How to Find Penny Stocks to Invest and Trade
ONSemi Is Marching Higher On Great Results
Profit From the Commercial Solar Boom? (Ad)
What Tyson Foods Q1 Means For Staples Stocks
Can Cummins Power To A New High? 
NASDAQ:KPTI

Karyopharm Therapeutics - KPTI Stock Forecast, Price & News

$3.37
-0.03 (-0.88%)
(As of 02/6/2023 12:00 AM ET)
Add
Compare
Today's Range
$3.29
$3.48
50-Day Range
$2.48
$5.29
52-Week Range
$2.45
$14.73
Volume
1.23 million shs
Average Volume
3.06 million shs
Market Capitalization
$273.48 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$9.33

Karyopharm Therapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.63 Rating Score
Upside/​Downside
177.0% Upside
$9.33 Price Target
Short Interest
Bearish
26.70% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.11
Upright™ Environmental Score
News Sentiment
0.42mentions of Karyopharm Therapeutics in the last 14 days
Based on 11 Articles This Week
Insider Trading
Selling Shares
$30,868 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($1.94) to ($1.33) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.25 out of 5 stars

Medical Sector

236th out of 1,027 stocks

Pharmaceutical Preparations Industry

106th out of 500 stocks

KPTI stock logo

About Karyopharm Therapeutics (NASDAQ:KPTI) Stock

Karyopharm Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. Its Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). Karyopharm's compound, XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. In addition to single-agent and combination activity against a variety of human cancers, SINE compounds have also shown biological activity in models of neurodegeneration, inflammation, autoimmune disease, certain viruses, and wound-healing. Karyopharm has several investigational programs in clinical or preclinical development.

Receive KPTI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Karyopharm Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

KPTI Stock News Headlines

Profit From the Commercial Solar Boom?
Solar energy had its best year ever in 2021, with a record 24 gigawatts of power installed. That's enough to power 18 million homes! Analysts expect the global solar farm market to reach $356 billion by 2028. The utility segment of the solar market is expected to grow at the highest annual growth rate in the industry, especially with the many tax incentives now offered.
Karyopharm Therapeutics (NASDAQ:KPTI) PT Lowered to $5.00
Profit From the Commercial Solar Boom?
Solar energy had its best year ever in 2021, with a record 24 gigawatts of power installed. That's enough to power 18 million homes! Analysts expect the global solar farm market to reach $356 billion by 2028. The utility segment of the solar market is expected to grow at the highest annual growth rate in the industry, especially with the many tax incentives now offered.
Karyopharm: Recent Sell-Off Hits A New Buy Target
Karyopharm: 6 Months Later, No Change In My Stance
Karyopharm Announces $165 Million Private Placement
Karyopharm Therapeutics Inc. (KPTI)
Expert Ratings for Karyopharm Therapeutics
Karyopharm to Participate at Upcoming Investor Conferences
See More Headlines
Receive KPTI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Karyopharm Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

KPTI Company Calendar

Last Earnings
11/03/2021
Today
2/06/2023
Next Earnings (Estimated)
2/14/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:KPTI
Fax
N/A
Employees
442
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$9.33
High Stock Price Forecast
$16.00
Low Stock Price Forecast
$5.00
Forecasted Upside/Downside
+177.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.63
Research Coverage
8 Analysts

Profitability

Net Income
$-124,090,000.00
Pretax Margin
-35.19%

Debt

Sales & Book Value

Annual Sales
$209.82 million
Book Value
($1.05) per share

Miscellaneous

Free Float
72,845,000
Market Cap
$273.48 million
Optionable
Optionable
Beta
-0.04

Key Executives

  • Richard A. Paulson
    President, CEO & Non-Executive Director
  • Mike Mason
    Chief Financial Officer, Treasurer & EVP
  • Reshma Rangwala
    Chief Medical Officer & Executive Vice President
  • Accumanno James
    Chief Compliance Officer
  • Tanya N. Lewis
    Chief Regulatory & Quality Officer, Executive VP













KPTI Stock - Frequently Asked Questions

Should I buy or sell Karyopharm Therapeutics stock right now?

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Karyopharm Therapeutics in the last year. There are currently 3 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" KPTI shares.
View KPTI analyst ratings
or view top-rated stocks.

What is Karyopharm Therapeutics' stock price forecast for 2023?

8 brokerages have issued 1-year price objectives for Karyopharm Therapeutics' shares. Their KPTI share price forecasts range from $5.00 to $16.00. On average, they expect the company's stock price to reach $9.33 in the next twelve months. This suggests a possible upside of 177.0% from the stock's current price.
View analysts price targets for KPTI
or view top-rated stocks among Wall Street analysts.

How have KPTI shares performed in 2023?

Karyopharm Therapeutics' stock was trading at $3.40 at the start of the year. Since then, KPTI stock has decreased by 0.9% and is now trading at $3.37.
View the best growth stocks for 2023 here
.

When is Karyopharm Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 14th 2023.
View our KPTI earnings forecast
.

How were Karyopharm Therapeutics' earnings last quarter?

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) issued its quarterly earnings results on Wednesday, November, 3rd. The company reported ($0.69) EPS for the quarter, missing analysts' consensus estimates of ($0.68) by $0.01. The company had revenue of $37.69 million for the quarter, compared to the consensus estimate of $25.84 million. During the same quarter last year, the firm earned ($0.73) earnings per share.

What guidance has Karyopharm Therapeutics issued on next quarter's earnings?

Karyopharm Therapeutics updated its FY 2022 earnings guidance on Monday, January, 9th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $157.70 million-$157.70 million, compared to the consensus revenue estimate of $161.68 million.

What is Michael Kauffman's approval rating as Karyopharm Therapeutics' CEO?

31 employees have rated Karyopharm Therapeutics Chief Executive Officer Michael Kauffman on Glassdoor.com. Michael Kauffman has an approval rating of 83% among the company's employees.

What other stocks do shareholders of Karyopharm Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Karyopharm Therapeutics investors own include NVIDIA (NVDA), Gilead Sciences (GILD), CRISPR Therapeutics (CRSP), Alibaba Group (BABA), Micron Technology (MU), Invitae (NVTA), Advanced Micro Devices (AMD), AbbVie (ABBV), Inovio Pharmaceuticals (INO) and Bristol-Myers Squibb (BMY).

What is Karyopharm Therapeutics' stock symbol?

Karyopharm Therapeutics trades on the NASDAQ under the ticker symbol "KPTI."

Who are Karyopharm Therapeutics' major shareholders?

Karyopharm Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include Birchview Capital LP (0.36%), Hennion & Walsh Asset Management Inc. (0.18%), Los Angeles Capital Management LLC (0.13%), New York State Common Retirement Fund (0.06%), Redwood Wealth Management Group LLC (0.04%) and Allspring Global Investments Holdings LLC (0.03%). Insiders that own company stock include Christopher Brett Primiano, Deepika Pakianathan, Garen G Bohlin, Jatin Shah, John Demaree, Mansoor Raza Mirza, Michael Kauffman, Michael Mason, Ran Frenkel, Richard A Paulson, Sharon Shacham, Sohanya Roshan Cheng, Stephen Mitchener and Tanya Lewis.
View institutional ownership trends
.

How do I buy shares of Karyopharm Therapeutics?

Shares of KPTI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Karyopharm Therapeutics' stock price today?

One share of KPTI stock can currently be purchased for approximately $3.37.

How much money does Karyopharm Therapeutics make?

Karyopharm Therapeutics (NASDAQ:KPTI) has a market capitalization of $273.48 million and generates $209.82 million in revenue each year. The company earns $-124,090,000.00 in net income (profit) each year or ($1.14) on an earnings per share basis.

How many employees does Karyopharm Therapeutics have?

The company employs 442 workers across the globe.

How can I contact Karyopharm Therapeutics?

Karyopharm Therapeutics' mailing address is 85 WELLS AVENUE SECOND FLOOR, NEWTON MA, 02459. The official website for the company is www.karyopharm.com. The company can be reached via phone at (617) 658-0600 or via email at ikarp@karyopharm.com.

This page (NASDAQ:KPTI) was last updated on 2/7/2023 by MarketBeat.com Staff